Former Deputy U.S. Trade Representative Mariam Sapiro has written a memo for the Pass USMCA Coalition arguing that the U.S.-Mexico-Canada Agreement (USMCA) would not prevent a future Congress from shortening the period of marketing exclusivity granted to new biologic medicines in the U.S. She argues that the countries could amend the agreement if the U.S. wanted to pass a law in violation of its current obligations.